{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ffc1fe6b303132625aa8d15/6ac775dc937a3c900fe1e504?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How should patients with ALL be selected for blinatumomab treatment?","description":"<p>The ALL Hub was pleased to speak with André Baruchel, Robert-Debré University Hospital, Paris, FR. We asked, How should patients with acute lymphoblastic leukemia (ALL) be selected for blinatumomab treatment? </p><p><br></p><p>In this interview, Baruchel discusses how patients with B-cell ALL should be selected for blinatumomab treatment. He highlights several considerations, including tumor burden, minimal residual disease response, CD19 expression, and patient fitness. He also discusses the role of blinatumomab as a chemotherapy-sparing treatment and as a bridge to allogeneic hematopoietic stem cell transplantation. </p><p><br></p><p><em>Intended for healthcare professionals. This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.</em> </p>","author_name":"Scientific Education Support"}